Aridhia's Data Platform Used in Major European Research Collaboration to Tackle Alzheimer's Dementia

AridhiaAridhia has announced that it is among 36 organisations behind a ground-breaking Innovative Medicines Initiative research programme that aims to build a platform for efficient testing of innovative treatments for the prevention of Alzheimer's dementia.

Aridhia's data and analytics platform, AnalytiXagility, has been selected for use in the European Prevention of Alzheimer's Dementia (EPAD) project, a powerful research collaboration between European organisations in the public and private sectors which, unlike previous projects, focuses on prevention of dementia in the early stages of the disease.

The project will collaborate with existing cohorts to create a register, identifying 24,000 people across Europe who may be at risk of developing the disease later in life. 6,000 of these people will be invited to join EPAD's cohort of 'at risk' subjects to undergo standardised tests and follow-ups. Of these, approximately 1,500 people will be selected to take part in EPAD's proof of concept adaptive trials of innovative drugs.

Rodrigo Barnes, Chief Technology Officer at Aridhia, said that AnalytiXagility has been chosen because it offers a strong collaborative platform that is accessible to all of the consortium partners and is able to carry out advanced data analytics that can interrogate any kind of data.

"AnalytiXagility offers EPAD a flexible working environment that is collaborative, neutral and has the ability to carry out advanced data analytics during complex trials.

"It will be used as part of a trial engine for the EPAD cohort of 6,000 subjects and the further 1,500 participants who will be asked to take part in the project’s proof of concept adaptive trials of drug candidates or drug combinations that have been specially designed to prevent Alzheimer's dementia.

"With no cure for Alzheimer's and little in the way of treatment, it is vital that we understand and learn how to prevent Alzheimer’s dementia when in its early phases."

The University of Edinburgh is working with Aridhia to trial the EPAD cohort. Professor Craig Ritchie, one of the project’s co-ordinators who is based at the University said: "EPAD is a game-changing project. There is commitment from a wide range of organisations across academia, pharma and public health, to get to the root causes of dementia, to understand how the disease develops over the decades before symptoms become visible, and treat patients at an early stage."

"The EPAD model gives us the opportunity to work together to understand who is more likely the get the disease and how they can be treated early, and effectively."

EPAD promises to deliver a more efficient research model which can streamline the recruitment of patients and enable likely drug candidates to be accelerated straight into Phase III trials, the last stage before a new drug is licenced for use.

Furthermore, all data collected from the cohort will be made public to allow researchers the chance to improve their understanding of the disease, especially in pre-symptomatic phases.

Aridhia's involvement in EPAD cements its commitment to globally significant collaborative research projects, and to addressing one of society’s most challenging diseases. Earlier this year the company announced that AnalytiXagility has been chosen to underpin the three year Moneta Research project, supporting their research into identifying people most likely to develop Alzheimer's dementia.

About Aridhia Informatics
Founded in 2007, Aridhia is a world-leading clinical and translational informatics company developing technology and capability that accelerates the translation of precision medicine and biomedical research into clinical practice. Operating internationally on projects in England, Scotland, Australia, and across Europe, Aridhia works closely with governments, health organisations, research collaborations and academic institutions to transform how care is delivered.

Based in Edinburgh and Glasgow, Aridhia has a 60-strong multidisciplinary team of data scientists, information governance specialists, computer scientists, software developers and healthcare experts.

About the Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.

Most Popular Now

Kick-off Meeting for eHealth Hub: An Int…

The Kick-off Meeting of the eHealth Hub project took place on the 20th and 21st of October 2016, in Murcia (Spain). The meeting effectively launched the activities of a newly...

Read more

HIV Test Performed on USB Stick

Scientists have developed a type of HIV test on a USB stick. The device, created by scientists at Imperial College London and DNA Electronics, uses a drop of blood to...

Read more

Major Health IT Event Opens with Recogni…

21 - 22 November 2016, Barcelona, Spain. The World of Health IT (WoHIT) has opened its doors to over 1,000 healthcare IT professionals from across 25 different countries worldwide. Covering a...

Read more

Emergency Video Telemedicine Positively …

Approximately 10 percent of newborns require help breathing after birth, and 1 in 1,000 newborns require more intensive resuscitation measures. These infrequent, high-risk deliveries may present challenges to community hospitals...

Read more

Crack the Human Brain

The time is ripe, the communication technology is available, for teams from different labs and different countries to join efforts and apply new forms of grassroots collaborative research in brain...

Read more

EC Open Call SC1-PM-15-2017: Personalise…

The activity aims at developing and validating radically new ICT based concepts and approaches for empowering and motivating people in need of guidance and care due to age related conditions...

Read more

MEDICA and COMPAMED 2016 Provide a Power…

14 - 17 November 2016, Düsseldorf, Germany. Once again, the world's biggest medical trade fair MEDICA and the leading international supplier trade fair COMPAMED, which take place in Düsseldorf, have provided...

Read more

Open Call SC1-HCO-08-2017: Actions to Br…

Despite serious efforts deployed at national and European level, the European Union sees significant internal disparities in terms of research and innovation performance as also identified in the Innovation Union...

Read more

Chronically Ill Women Underusing Online …

Barriers to internet use may be preventing chronically ill middle-aged and older women from being as healthy as they otherwise could be, new research suggests. The study conducted by researchers...

Read more

MEDICA 2016 + COMPAMED 2016 with over 5…

14 - 17 November 2016, Düsseldorf, Germany. When top decision-makers in the healthcare business meet in Düsseldorf again in the middle of November at the world's leading medical trade fair, MEDICA...

Read more

The International Health Industry Comes …

14 - 17 November 2016, Düsseldorf, Germany. Decision makers from all sectors of the international health industry meet again in Düsseldorf from Monday to Thursday. The world's biggest medical trade fair...

Read more

Health at a Glance: Europe 2016

This publication is the result of a close co-operation between the OECD and the European Commission and is the first step in the Commission's "State of Health in the EU...

Read more
(HEALTH IT) SPACE - Take a look at who has just Joined